NASDAQ:MDWD - Mediwound Stock Price, Forecast & News

Mediwound trades on the NASDAQ under the ticker symbol "MDWD."

Mediwound Ltd (NASDAQ:MDWD) issued its quarterly earnings results on Thursday, November, 14th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.12. The biopharmaceutical company had revenue of $5.14 million for the quarter, compared to the consensus estimate of $2.67 million. Mediwound had a net margin of 69.50% and a negative return on equity of 94.57%. View Mediwound's Earnings History.

Mediwound is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Mediwound.

2 equities research analysts have issued twelve-month price objectives for Mediwound's shares. Their forecasts range from $5.50 to $7.00. On average, they anticipate Mediwound's share price to reach $6.25 in the next year. This suggests a possible upside of 105.6% from the stock's current price. View Analyst Price Targets for Mediwound.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mediwound.

Media coverage about MDWD stock has been trending somewhat negative on Monday, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mediwound earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Mediwound.

Some companies that are related to Mediwound include Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF), GLG Life Tech (GLGLF), True Drinks (TRUU), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO), Beleave (BE) and Beleave (BE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mediwound investors own include Opko Health (OPK), Blackstone Group (BX), Wells Fargo & Co (WFC), Mastercard (MA), Caesarstone (CSTE), Chubb (CB), Nordic American Tanker (NAT), Novavax (NVAX), Braskem (BRKMY) and Gilead Sciences (GILD).

Mediwound's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Harel Insurance Investments & Financial Services Ltd. (1.87%).

MDWD stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd..

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MDWD stock can currently be purchased for approximately $3.04.

Mediwound has a market capitalization of $82.62 million and generates $3.40 million in revenue each year. The biopharmaceutical company earns $-1,060,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Mediwound employs 73 workers across the globe.View Additional Information About Mediwound.

The official website for Mediwound is http://www.mediwound.com/.

Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]